PMID- 33247941
OWN - NLM
STAT- MEDLINE
DCOM- 20210510
LR  - 20210510
IS  - 1600-0404 (Electronic)
IS  - 0001-6314 (Linking)
VI  - 143
IP  - 4
DP  - 2021 Apr
TI  - Cerebrospinal fluid cytokines and metalloproteinases in cerebral amyloid 
      angiopathy-related inflammation.
PG  - 450-457
LID - 10.1111/ane.13382 [doi]
AB  - OBJECTIVES: To clarify pathomechanisms of cerebral amyloid angiopathy-related 
      inflammation/vasculitis (CAA-ri). METHODS: We collected cerebrospinal fluid (CSF) 
      samples of nine patients with CAA-ri of before (acute CAA-ri group) and after 
      treatment (post-treatment CAA-ri group) and nine patients with CAA (CAA without 
      inflammation group). We examined anti-amyloid beta protein (Abeta) antibody titer by 
      ELISA, and measured 27 Cytokines, nine matrix metalloproteinases (MMPs), and four 
      tissue inhibitors of MMPs (TIMPs) by multiplexed fluorescent bead-based 
      immunoassay. RESULTS: We demonstrated TIMP-2 (median) in CSF of the acute CAA-ri 
      group (30,994.49 pg/ml, p = 0.007) and the post-treatment CAA-ri group 
      (36,430.97 pg/ml, p = 0.001) was significantly elevated compared to that of the 
      CAA without inflammation group (22,013.58 pg/ml). TIMP-1 was also higher in the 
      post-treatment CAA-ri group than that in the CAA without inflammation group 
      (58,167.75 pg/ml vs. 45,770.03 pg/ml, p = 0.005). There was a significant 
      positive correlation between TIMP-1 and anti-Abeta antibodies in CAA-ri (r(s) 
       = 0.900, p = 0.037). Median MMP-2 tended to be higher in the acute and 
      post-treatment CAA-ri groups (10,619.82 pg/ml and 8396.98 pg/ml, respectively) 
      than in the CAA without inflammation group (4436.34 pg/ml). Platelet-derived 
      growth factor (PDGF)-BB levels before treatment were higher than those after 
      treatment (median, 12.66 pg/ml vs. 6.39 pg/ml; p = 0.011) and correlated with the 
      titer of anti-Abeta antibodies (r(s)  =0.900, p = 0.037). CONCLUSIONS: Elevated 
      levels of MMP-2, TIMP-1, and TIMP-2 might be related to the development of 
      CAA-ri. Elevation of PDGF-BB could be a useful marker for clinical diagnosis of 
      CAA-ri.
CI  - (c) 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
FAU - Sakai, Kenji
AU  - Sakai K
AUID- ORCID: 0000-0002-8865-4097
AD  - Department of Neurology and Neurobiology of Aging, Kanazawa University Graduate 
      School of Medical Sciences, Kanazawa, Japan.
FAU - Noguchi-Shinohara, Moeko
AU  - Noguchi-Shinohara M
AD  - Department of Neurology and Neurobiology of Aging, Kanazawa University Graduate 
      School of Medical Sciences, Kanazawa, Japan.
AD  - Department of Preemptive Medicine for Dementia, Kanazawa University Graduate 
      School of Medical Sciences, Kanazawa, Japan.
FAU - Ikeda, Tokuhei
AU  - Ikeda T
AD  - Department of Neurology and Neurobiology of Aging, Kanazawa University Graduate 
      School of Medical Sciences, Kanazawa, Japan.
AD  - Department of Neurology, Ishikawa Prefectural Central Hospital, Kanazawa, Japan.
FAU - Hamaguchi, Tsuyoshi
AU  - Hamaguchi T
AD  - Department of Neurology and Neurobiology of Aging, Kanazawa University Graduate 
      School of Medical Sciences, Kanazawa, Japan.
FAU - Ono, Kenjiro
AU  - Ono K
AD  - Department of Neurology and Neurobiology of Aging, Kanazawa University Graduate 
      School of Medical Sciences, Kanazawa, Japan.
AD  - Department of Neurology, Showa University School of Medicine, Tokyo, Japan.
FAU - Yamada, Masahito
AU  - Yamada M
AD  - Department of Neurology and Neurobiology of Aging, Kanazawa University Graduate 
      School of Medical Sciences, Kanazawa, Japan.
LA  - eng
GR  - Takeda Science Foundation/
GR  - JP26860234/JSPS KAKENHI/
GR  - The Amyloidosis Research Committee, Intractable Disease Division of the Japanese 
      Ministry of Health and Welfare/
GR  - H21-Nanchi-Ippan-072/The Research Committee on Collection of Biosamples from 
      Patients with CAA on Intractable Diseases from the Ministry of Health, Labour, 
      and Welfare/
PT  - Journal Article
DEP - 20201211
PL  - Denmark
TA  - Acta Neurol Scand
JT  - Acta neurologica Scandinavica
JID - 0370336
RN  - 0 (Amyloid beta-Peptides)
RN  - 0 (Biomarkers)
RN  - 0 (Cytokines)
RN  - 0 (Inflammation Mediators)
RN  - EC 3.4.- (Metalloproteases)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Amyloid beta-Peptides/cerebrospinal fluid
MH  - Biomarkers/cerebrospinal fluid
MH  - Cerebral Amyloid Angiopathy/*cerebrospinal fluid/*diagnosis
MH  - Cytokines/*cerebrospinal fluid
MH  - Female
MH  - Humans
MH  - Inflammation Mediators/*cerebrospinal fluid
MH  - Male
MH  - Metalloproteases/*cerebrospinal fluid
MH  - Retrospective Studies
OTO - NOTNLM
OT  - cerebral amyloid angiopathy
OT  - inflammation
OT  - matrix metalloproteinase
OT  - platelet-derived growth factor
OT  - tissue inhibitor of matrix proteinase
OT  - vasculitis
EDAT- 2020/11/29 06:00
MHDA- 2021/05/11 06:00
CRDT- 2020/11/28 17:04
PHST- 2020/08/29 00:00 [received]
PHST- 2020/11/06 00:00 [revised]
PHST- 2020/11/21 00:00 [accepted]
PHST- 2020/11/29 06:00 [pubmed]
PHST- 2021/05/11 06:00 [medline]
PHST- 2020/11/28 17:04 [entrez]
AID - 10.1111/ane.13382 [doi]
PST - ppublish
SO  - Acta Neurol Scand. 2021 Apr;143(4):450-457. doi: 10.1111/ane.13382. Epub 2020 Dec 
      11.